{"id":"NCT03201003","sponsor":"Aimmune Therapeutics, Inc.","briefTitle":"ARTEMIS Peanut Allergy In Children","officialTitle":"AR101 Trial in Europe Measuring Oral Immunotherapy Success in Peanut Allergic Children (ARTEMIS)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-06-12","primaryCompletion":"2019-02-15","completion":"2019-02-15","firstPosted":"2017-06-28","resultsPosted":"2021-08-03","lastUpdate":"2021-08-03"},"enrollment":175,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Peanut Allergy"],"interventions":[{"type":"BIOLOGICAL","name":"AR101 powder provided in capsules & sachets","otherNames":[]},{"type":"OTHER","name":"Placebo powder provided in capsules & sachets","otherNames":[]}],"arms":[{"label":"AR101","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate the efficacy and safety of AR101 through oral immunotherapy (OIT) in peanut-allergic children.","primaryOutcome":{"measure":"The Proportion of Subjects Ages 4-17 Who Tolerated a Single Highest Dose of at Least 1000 mg in the Exit Oral Food Challenge.","timeFrame":"Approximately 9 months","effectByArm":[{"arm":"AR101","deltaMin":77,"sd":null},{"arm":"Placebo","deltaMin":1,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"4 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":6},"locations":{"siteCount":18,"countries":["France","Germany","Ireland","Italy","Spain","Sweden","United Kingdom"]},"refs":{"pmids":["36915184","34389504","34320250","32702315"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":132},"commonTop":["Abdominal pain","Cough","Pruritus","Nausea","Throat irritation"]}}